Jincy Immanuel1, David Simmons2. 1. School of Medicine, Western Sydney University, Locked Bag 1797, Campbelltown, NSW, 2751, Australia. 2. School of Medicine, Western Sydney University, Locked Bag 1797, Campbelltown, NSW, 2751, Australia. da.simmons@westernsydney.edu.au.
Abstract
PURPOSE OF REVIEW: We conducted a systematic review to evaluate the current evidence for screening and treatment for early-onset gestational diabetes mellitus (GDM) RECENT FINDINGS: Many of the women with early GDM in the first trimester do not have evidence of hyperglycemia at 24-28 weeks' gestation. A high proportion (15-70%) of women with GDM can be detected early in pregnancy depending on the setting, criteria used and screening strategy. However, there remains no good evidence for any of the diagnostic criteria for early-onset GDM. In a meta-analysis of 13 cohort studies, perinatal mortality (relative risk (RR) 3.58 [1.91, 6.71]), neonatal hypoglycemia (RR 1.61 [1.02, 2.55]), and insulin use (RR 1.71 [1.45, 2.03]) were greater among early-onset GDM women compared to late-onset GDM women, despite treatment. Considering the high likelihood of benefit from treatment, there is an urgent need for randomized controlled trials that investigate any benefits and possible harms of treatment of early-onset GDM.
PURPOSE OF REVIEW: We conducted a systematic review to evaluate the current evidence for screening and treatment for early-onset gestational diabetes mellitus (GDM) RECENT FINDINGS: Many of the women with early GDM in the first trimester do not have evidence of hyperglycemia at 24-28 weeks' gestation. A high proportion (15-70%) of women with GDM can be detected early in pregnancy depending on the setting, criteria used and screening strategy. However, there remains no good evidence for any of the diagnostic criteria for early-onset GDM. In a meta-analysis of 13 cohort studies, perinatal mortality (relative risk (RR) 3.58 [1.91, 6.71]), neonatal hypoglycemia (RR 1.61 [1.02, 2.55]), and insulin use (RR 1.71 [1.45, 2.03]) were greater among early-onset GDM women compared to late-onset GDM women, despite treatment. Considering the high likelihood of benefit from treatment, there is an urgent need for randomized controlled trials that investigate any benefits and possible harms of treatment of early-onset GDM.
Authors: Caroline A Crowther; Janet E Hiller; John R Moss; Andrew J McPhee; William S Jeffries; Jeffrey S Robinson Journal: N Engl J Med Date: 2005-06-12 Impact factor: 91.245
Authors: J Seth Hawkins; Julie Y Lo; Brian M Casey; Donald D McIntire; Kenneth J Leveno Journal: Am J Obstet Gynecol Date: 2008-03 Impact factor: 8.661
Authors: J L Mills; L Jovanovic; R Knopp; J Aarons; M Conley; E Park; Y J Lee; L Holmes; J L Simpson; B Metzger Journal: Metabolism Date: 1998-09 Impact factor: 8.694
Authors: V Seshiah; Alexander Cynthia; V Balaji; Madhuri S Balaji; S Ashalata; Rajan Sheela; M Thamizharasi; T Arthi Journal: Diabetes Res Clin Pract Date: 2008-02-04 Impact factor: 5.602
Authors: Deborah J Wexler; Camille E Powe; Linda A Barbour; Thomas Buchanan; Donald R Coustan; Rosa Corcoy; Peter Damm; Fidelma Dunne; Denice S Feig; Assiamira Ferrara; Lorie M Harper; Mark B Landon; Sara J Meltzer; Boyd E Metzger; Hilary Roeder; Janet A Rowan; David A Sacks; David Simmons; Jason G Umans; Patrick M Catalano Journal: Obstet Gynecol Date: 2018-08 Impact factor: 7.661
Authors: Leanne M Redman; Kimberly L Drews; Samuel Klein; Linda Van Horn; Rena R Wing; Xavier Pi-Sunyer; Mary Evans; Kaumudi Joshipura; S Sonia Arteaga; Alison G Cahill; Rebecca G Clifton; Kimberly A Couch; Paul W Franks; Dympna Gallagher; Debra Haire-Joshu; Corby K Martin; Alan M Peaceman; Suzanne Phelan; Elizabeth A Thom; Susan Z Yanovski; William C Knowler Journal: Diabetes Res Clin Pract Date: 2020-11-22 Impact factor: 8.180